Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Britain Courts Anthropic Amid US Defense Department Dispute 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
NORCROSS, Ga., Dec. 08, 2016 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company will present a corporate update via live webcast immediately following the business portion of its 2016 Annual Meeting of Stockholders. Peter Traber, M.D., president, chief executive officer and chief medical officer, will provide an overview of the progress achieved over the past year, as well as the Company’s plans and strategy for the upcoming year, especially its seminal NASH-CX Trial. The webcast is expected to commence at approximately 1:30 p.m. ET on Thursday, December 15, 2016.
The webcast can be accessed via the investor relations portion of the Galectin Therapeutics website at http://investor.galectintherapeutics.com/. The webcast may also be accessed directly via the following link: https://dentons.adobeconnect.com/galt_board/. The presentation may also be heard via teleconference by dialing 866-225-1342 (within the United States). A list of international dial-in numbers can be found here. The passcode for participants is 8620018752. Please log in approximately 10 minutes before the event to ensure a timely connection.
The webcast will also be archived on the Company's website.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Contact Jack Callicutt, Chief Financial Officer (678) 620-3186 [email protected]
